Yuki Shimizu
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization.
Journal: NPJ precision oncology
Published: October 30, 2023
Acquired resistance to BRAF inhibitors is mediated by BRAF splicing variants in BRAF V600E mutation-positive colorectal neuroendocrine carcinoma.
Journal: Cancer letters
Published: April 12, 2022
GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer.
Journal: NPJ precision oncology
Published: September 04, 2021
Naturally occurring small molecule compounds that target histone deacetylases and their potential applications in cancer therapy.
Journal: The Journal of antibiotics
Published: April 08, 2021
U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 28, 2020
Joint-Preserving Surgery for Hyperextension Deformity of the Hallux Interphalangeal Joint in a Patient with Rheumatoid Arthritis.
Journal: Case reports in orthopedics
Published: March 12, 2020
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.
Journal: Nature communications
Published: September 14, 2018
Showing 1-8 of 8
Last Updated: 09/26/2026